Literature DB >> 19132515

Combining MCMC with 'sequential' PKPD modelling.

David Lunn1, Nicky Best, David Spiegelhalter, Gordon Graham, Beat Neuenschwander.   

Abstract

We introduce a method for preventing unwanted feedback in Bayesian PKPD link models. We illustrate the approach using a simple example on a single individual, and subsequently demonstrate the ease with which it can be applied to more general settings. In particular, we look at the three 'sequential' population PKPD models examined by Zhang et al. (J Pharmacokinet Pharmacodyn 30:387-404, 2003; J Pharmacokinet Pharmacodyn 30:405-416, 2003), and provide graphical representations of these models to elucidate their structure. An important feature of our approach is that it allows uncertainty regarding the PK parameters to propagate through to inferences on the PD parameters. This is in contrast to standard two-stage approaches whereby 'plug-in' point estimates for either the population or the individual-specific PK parameters are required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19132515     DOI: 10.1007/s10928-008-9109-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  10 in total

1.  Determination of an optimal dosage regimen using a Bayesian decision analysis of efficacy and adverse effect data.

Authors:  Gordon Graham; Suneel Gupta; Leon Aarons
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-02       Impact factor: 2.745

2.  Bayesian analysis of population PK/PD models: general concepts and software.

Authors:  David J Lunn; Nicky Best; Andrew Thomas; Jon Wakefield; David Spiegelhalter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2002-06       Impact factor: 2.745

3.  Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheinerz
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

4.  Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.

Authors:  Liping Zhang; Stuart L Beal; Lewis B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-12       Impact factor: 2.745

5.  Stochastic relaxation, gibbs distributions, and the bayesian restoration of images.

Authors:  S Geman; D Geman
Journal:  IEEE Trans Pattern Anal Mach Intell       Date:  1984-06       Impact factor: 6.226

6.  Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.

Authors:  Ivelina Gueorguieva; Leon Aarons; Malcolm Rowland
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-29       Impact factor: 2.745

7.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

8.  A population analysis of the pharmacokinetics and pharmacodynamics of midazolam in the rat.

Authors:  L Aarons; J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1991-10

9.  The pharmacokinetics of saquinavir: a Markov chain Monte Carlo population analysis.

Authors:  D J Lunn; L Aarons
Journal:  J Pharmacokinet Biopharm       Date:  1998-02

10.  Estimation of population pharmacokinetic parameters in the presence of non-compliance.

Authors:  Song Mu; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

  10 in total
  20 in total

1.  Calibration of complex models through Bayesian evidence synthesis: a demonstration and tutorial.

Authors:  Christopher H Jackson; Mark Jit; Linda D Sharples; Daniela De Angelis
Journal:  Med Decis Making       Date:  2013-07-25       Impact factor: 2.583

2.  Measurement error in two-stage analyses, with application to air pollution epidemiology.

Authors:  Adam A Szpiro; Christopher J Paciorek
Journal:  Environmetrics       Date:  2013-12-01       Impact factor: 1.900

3.  Swift block-updating EM and pseudo-EM procedures for Bayesian shrinkage analysis of quantitative trait loci.

Authors:  Crispin M Mutshinda; Mikko J Sillanpää
Journal:  Theor Appl Genet       Date:  2012-07-24       Impact factor: 5.699

4.  Application of Markov chain Monte Carlo analysis to biomathematical modeling of respirable dust in US and UK coal miners.

Authors:  Lisa M Sweeney; Ann Parker; Lynne T Haber; C Lang Tran; Eileen D Kuempel
Journal:  Regul Toxicol Pharmacol       Date:  2013-02-27       Impact factor: 3.271

5.  The Central Role of Bayes' Theorem for Joint Estimation of Causal Effects and Propensity Scores.

Authors:  Corwin Matthew Zigler
Journal:  Am Stat       Date:  2015-12-14       Impact factor: 8.710

6.  Bayesian evaluation of a physiologically-based pharmacokinetic (PBPK) model of long-term kinetics of metal nanoparticles in rats.

Authors:  Lisa M Sweeney; Laura MacCalman; Lynne T Haber; Eileen D Kuempel; C Lang Tran
Journal:  Regul Toxicol Pharmacol       Date:  2015-07-03       Impact factor: 3.271

7.  Quantitative Systems Pharmacology: A Framework for Context.

Authors:  Ioannis P Androulakis
Journal:  Curr Pharmacol Rep       Date:  2016-04-08

8.  Hierarchical Adaptive Regression Kernels for Regression with Functional Predictors.

Authors:  Dawn B Woodard; Ciprian Crainiceanu; David Ruppert
Journal:  J Comput Graph Stat       Date:  2013       Impact factor: 2.302

9.  Bayesian Model Averaging for Propensity Score Analysis.

Authors:  David Kaplan; Jianshen Chen
Journal:  Multivariate Behav Res       Date:  2014 Nov-Dec       Impact factor: 5.923

10.  Estimating the prevalence of transmitted HIV drug resistance using pooled samples.

Authors:  Mariel M Finucane; Christopher F Rowley; Christopher J Paciorek; Max Essex; Marcello Pagano
Journal:  Stat Methods Med Res       Date:  2013-02-01       Impact factor: 3.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.